Kodiak Sciences Inc (KOD)

$35.94 +1.85 (5.43%)
Market Cap 2.25B
Revenue (ttm) 0.00
Net Income (ttm) -229.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,591,100
Avg Vol 716,506
Day's Range N/A - N/A
Shares Out 62.58M
Stochastic %K 56%
Beta 2.21
Analysts Strong Sell
Price Target $59.00

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 281 0850
Website: kodiak.com
Address:
1250 Page Mill Road, Palo Alto, United States
Stekli27
Stekli27 Jun. 26 at 8:02 PM
$KOD wtf is the volume st the end. BO coming? 😆
2 · Reply
RandomInvestor777
RandomInvestor777 Jun. 26 at 3:41 PM
$KOD the issue is daybreak readout is very risky imo, GLOW 2 was like a 90% probability of success. This is the major overhang, Will it win over eyela?
0 · Reply
kpletely
kpletely Jun. 25 at 6:37 PM
$KOD no reason for drop, people undervaluing duration and improved safety imo
1 · Reply
Snackdaddy
Snackdaddy Jun. 25 at 6:10 PM
$KOD massive dump today. probably more tomorrow. can we see under $30 again?
0 · Reply
TMCtoMars
TMCtoMars Jun. 25 at 2:25 PM
$KOD starting to recover from the profit taking after the initial hype from the March results. hoping we are now heading to maybe $50 range over next few months in anticipation of the September results? What do we think?
2 · Reply
Cutlass
Cutlass Jun. 25 at 1:55 PM
$KOD 👀👍
0 · Reply
BB_88_
BB_88_ Jun. 23 at 6:30 PM
$KOD short in to close
0 · Reply
spinusn27
spinusn27 Jun. 23 at 4:43 PM
$OCUL getting perky 💪💪. Reminds me of the good old days with $KOD
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 22 at 6:25 PM
$MLTX trades at meaningfully lower multiples of analyst consensus versus 6 peers with near term Phase 3 data reads. $DFTX reported solid Phase 3 data as well. Note: Share price & market cap are intra-day 6/22/26. We Googled "Sonelokimab patent expiration" & the results suggested MLTX's IP is good thru FY40 yet analyst consensus drops in FY35 from FY34. Any guidance on MLTX would be appreciated? We thought MLTX reported disappointing data at the end of Q325. $IRON & $AMLX trade at the highest multiples in this peer group. $KOD trades at the 2nd lowest multiple in this specific peer group.
3 · Reply
BB_88_
BB_88_ Jun. 22 at 6:04 PM
$KOD short 37.99 in to close
1 · Reply
Latest News on KOD
Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 24 days ago

Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2026

Kodiak Sciences Slides: FY 2026

Jun 4, 2026, 11:40 AM EDT - 24 days ago

Kodiak Sciences Slides: FY 2026

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

May 28, 2026, 6:09 PM EDT - 4 weeks ago

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Kodiak Sciences upgraded to Buy from Neutral at Chardan

2026-05-11T16:59:46.000Z - 6 weeks ago

Kodiak Sciences upgraded to Buy from Neutral at Chardan

Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)

2026-05-07T21:46:34.000Z - 7 weeks ago

Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

May 7, 2026, 4:00 PM EDT - 7 weeks ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 7 weeks ago

Kodiak Sciences Earnings release: Q1 2026

Kodiak Sciences Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 7 weeks ago

Kodiak Sciences Quarterly report: Q1 2026

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

May 1, 2026, 12:23 AM EDT - 2 months ago

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Kodiak Sciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Kodiak Sciences Proxy statement: Proxy filing

Kodiak Sciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Kodiak Sciences Proxy statement: Proxy filing

Kodiak Sciences falls -8.7%

2026-04-02T16:07:19.000Z - 3 months ago

Kodiak Sciences falls -8.7%

Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings

2026-04-01T16:27:41.000Z - 3 months ago

Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings

Kodiak Sciences reports Q4 EPS ($1.05) vs (84c) last year

2026-04-01T15:15:17.000Z - 3 months ago

Kodiak Sciences reports Q4 EPS ($1.05) vs (84c) last year

Kodiak Sciences rises 10.7%

2026-04-01T14:07:48.000Z - 3 months ago

Kodiak Sciences rises 10.7%

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Mar 31, 2026, 4:45 PM EDT - 3 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 3 months ago

Kodiak Sciences Annual report: Q4 2025

Kodiak Sciences Earnings release: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 3 months ago

Kodiak Sciences Earnings release: Q4 2025

Kodiak Sciences: Road To $120

Mar 30, 2026, 10:00 AM EDT - 3 months ago

Kodiak Sciences: Road To $120

Kodiak Sciences price target raised to $80 from $50 at UBS

2026-03-27T13:29:25.000Z - 3 months ago

Kodiak Sciences price target raised to $80 from $50 at UBS

Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright

2026-03-27T10:05:12.000Z - 3 months ago

Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright

Kodiak Sciences price target raised to $56 from $39 at Jefferies

2026-03-26T18:10:55.000Z - 3 months ago

Kodiak Sciences price target raised to $56 from $39 at Jefferies

Kodiak Sciences stock soars over 60%: what's behind the sharp rally

Mar 26, 2026, 12:33 PM EDT - 3 months ago

Kodiak Sciences stock soars over 60%: what's behind the sharp rally

Morning Movers: Kodiak Sciences skyrockets following GLOW2 study results

2026-03-26T13:00:50.000Z - 3 months ago

Morning Movers: Kodiak Sciences skyrockets following GLOW2 study results

CMC CRBG DBI EQH LOVE MLKN NAVN

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Mar 26, 2026, 8:12 AM EDT - 3 months ago

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Kodiak Sciences reports GLOW2 study of Zenkuda met primary endpoint

2026-03-26T12:00:30.000Z - 3 months ago

Kodiak Sciences reports GLOW2 study of Zenkuda met primary endpoint

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Mar 26, 2026, 6:00 AM EDT - 3 months ago

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Kodiak Sciences Slides: Corporate presentation

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Kodiak Sciences Slides: Corporate presentation

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Feb 4, 2026, 7:00 AM EST - 5 months ago

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 5 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX LITE

Kodiak Sciences price target raised to $38 from $26 at H.C. Wainwright

2026-01-22T11:11:04.000Z - 5 months ago

Kodiak Sciences price target raised to $38 from $26 at H.C. Wainwright

Kodiak Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 5 months ago

Kodiak Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Kodiak Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 5 months ago

Kodiak Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:19 PM EST - 6 months ago

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Kodiak Sciences assumed with a Buy at UBS

2026-01-07T13:20:26.000Z - 6 months ago

Kodiak Sciences assumed with a Buy at UBS

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 18, 2025, 8:26 PM EST - 6 months ago

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Kodiak Sciences 6.956M share Spot Secondary priced at $23.00

2025-12-17T11:11:47.000Z - 6 months ago

Kodiak Sciences 6.956M share Spot Secondary priced at $23.00

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Dec 16, 2025, 10:55 PM EST - 6 months ago

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Kodiak Sciences Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 6 months ago

Kodiak Sciences Announces Proposed Public Offering of Common Stock

Kodiak Sciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:00 PM EST - 7 months ago

Kodiak Sciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 11:30 AM EST - 7 months ago

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2025

Kodiak Sciences Slides: FY 2025

Nov 17, 2025, 11:30 AM EST - 7 months ago

Kodiak Sciences Slides: FY 2025

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 13, 2025, 4:05 PM EST - 8 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Kodiak Sciences Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

Kodiak Sciences Earnings release: Q3 2025

Kodiak Sciences Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

Kodiak Sciences Quarterly report: Q3 2025

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 12, 2025, 5:48 PM EST - 8 months ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Nov 5, 2025, 7:00 AM EST - 8 months ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

The Big 3: GOOGL, KOD, FTK

Oct 31, 2025, 12:01 PM EDT - 8 months ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 15, 2025, 7:00 AM EDT - 10 months ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 10:40 AM EDT - 10 months ago

Harbour BioMed Reports 2025 Interim Results

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 19, 2025, 2:18 PM EDT - 11 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Kodiak Sciences Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Kodiak Sciences Quarterly report: Q2 2025

Kodiak Sciences Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Kodiak Sciences Earnings release: Q2 2025

Kodiak Sciences Transcript: R&D Day 2025

Jul 16, 2025, 1:00 PM EDT - 1 year ago

Kodiak Sciences Transcript: R&D Day 2025

Kodiak Sciences Slides: FY 2025

Jul 16, 2025, 1:00 PM EDT - 1 year ago

Kodiak Sciences Slides: FY 2025

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

Jun 25, 2025, 4:45 PM EDT - 1 year ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2025

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025, 9:32 PM EDT - 1 year ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

Kodiak Sciences Quarterly report: Q1 2025

May 22, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Quarterly report: Q1 2025

Kodiak Sciences Earnings release: Q1 2025

May 22, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Earnings release: Q1 2025

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 14, 2025, 4:15 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

May 1, 2025, 11:43 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Kodiak Sciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences Proxy statement: Proxy Filing

Kodiak Sciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences Proxy statement: Proxy Filing

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Kodiak Sciences Annual report: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

Kodiak Sciences Annual report: Q4 2024

Kodiak Sciences Earnings release: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

Kodiak Sciences Earnings release: Q4 2024

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Mar 10, 2025, 4:39 PM EDT - 1 year ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Feb 4, 2025, 7:30 AM EST - 1 year ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Kodiak Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Kodiak Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Kodiak Sciences Slides: FY 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Kodiak Sciences Slides: FY 2025

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 6:00 AM EST - 1 year ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kodiak Sciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 2:35 PM EST - 1 year ago

Kodiak Sciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2024

Nov 21, 2024, 4:00 AM EST - 1 year ago

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2024

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Kodiak Sciences Earnings release: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Kodiak Sciences Earnings release: Q3 2024

Kodiak Sciences Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Kodiak Sciences Quarterly report: Q3 2024

Kodiak Sciences to Participate in Upcoming Investor Conferences

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Kodiak Sciences to Present at Innovate Retina 2024

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Kodiak Sciences Transcript: R&D Day 2024

Sep 23, 2024, 10:30 AM EDT - 1 year ago

Kodiak Sciences Transcript: R&D Day 2024

Kodiak Sciences Slides: FY 2024

Sep 23, 2024, 10:30 AM EDT - 1 year ago

Kodiak Sciences Slides: FY 2024

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Aug 14, 2024, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Kodiak Sciences Quarterly report: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 2 years ago

Kodiak Sciences Quarterly report: Q2 2024

Kodiak Sciences Earnings release: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q2 2024

Kodiak Sciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 13, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Kodiak Sciences Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Transcript: Jefferies 2024 Global Healthcare Conference

Kodiak Sciences Slides: FY 2024

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Slides: FY 2024

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 29, 2024, 4:36 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

Kodiak Sciences Quarterly report: Q1 2024

May 15, 2024, 4:15 PM EDT - 2 years ago

Kodiak Sciences Quarterly report: Q1 2024

Kodiak Sciences Earnings release: Q1 2024

May 15, 2024, 4:15 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q1 2024

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 15, 2024, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 13, 2024, 7:32 PM EDT - 2 years ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

May 2, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Proxy statement: Proxy Filing

Kodiak Sciences Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Proxy statement: Proxy Filing

Kodiak Sciences Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Earnings Call Transcript: Q4 2023

Kodiak Sciences Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Annual report: Q4 2023

Kodiak Sciences Earnings release: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q4 2023

Kodiak Sciences Slides: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Slides: Q4 2023

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 6:30 AM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Mar 26, 2024, 6:15 AM EDT - 2 years ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 30, 2024, 6:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Kodiak Sciences Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Kodiak Sciences Quarterly report: Q3 2023

Kodiak Sciences Earnings release: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Kodiak Sciences Earnings release: Q3 2023

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Stekli27
Stekli27 Jun. 26 at 8:02 PM
$KOD wtf is the volume st the end. BO coming? 😆
2 · Reply
RandomInvestor777
RandomInvestor777 Jun. 26 at 3:41 PM
$KOD the issue is daybreak readout is very risky imo, GLOW 2 was like a 90% probability of success. This is the major overhang, Will it win over eyela?
0 · Reply
kpletely
kpletely Jun. 25 at 6:37 PM
$KOD no reason for drop, people undervaluing duration and improved safety imo
1 · Reply
Snackdaddy
Snackdaddy Jun. 25 at 6:10 PM
$KOD massive dump today. probably more tomorrow. can we see under $30 again?
0 · Reply
TMCtoMars
TMCtoMars Jun. 25 at 2:25 PM
$KOD starting to recover from the profit taking after the initial hype from the March results. hoping we are now heading to maybe $50 range over next few months in anticipation of the September results? What do we think?
2 · Reply
Cutlass
Cutlass Jun. 25 at 1:55 PM
$KOD 👀👍
0 · Reply
BB_88_
BB_88_ Jun. 23 at 6:30 PM
$KOD short in to close
0 · Reply
spinusn27
spinusn27 Jun. 23 at 4:43 PM
$OCUL getting perky 💪💪. Reminds me of the good old days with $KOD
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 22 at 6:25 PM
$MLTX trades at meaningfully lower multiples of analyst consensus versus 6 peers with near term Phase 3 data reads. $DFTX reported solid Phase 3 data as well. Note: Share price & market cap are intra-day 6/22/26. We Googled "Sonelokimab patent expiration" & the results suggested MLTX's IP is good thru FY40 yet analyst consensus drops in FY35 from FY34. Any guidance on MLTX would be appreciated? We thought MLTX reported disappointing data at the end of Q325. $IRON & $AMLX trade at the highest multiples in this peer group. $KOD trades at the 2nd lowest multiple in this specific peer group.
3 · Reply
BB_88_
BB_88_ Jun. 22 at 6:04 PM
$KOD short 37.99 in to close
1 · Reply
BB_88_
BB_88_ Jun. 22 at 4:08 PM
$KOD short here will retrace
1 · Reply
RandomInvestor777
RandomInvestor777 Jun. 22 at 3:12 PM
$KOD not sure how reliable this is ? https://www.forbes.com/sites/greatspeculations/2026/03/30/kodiak-sciences-road-to-120/
0 · Reply
PlutoAnalyses
PlutoAnalyses Jun. 19 at 9:22 PM
$OCUL Working in the article right now. Drop below if there are any specific topics that you would really want to be covered. Personaly I am curious about to what extent they are competing with $KOD, which was my first 10x. $IBB $XBI
1 · Reply
bxlams
bxlams Jun. 17 at 9:31 PM
$KOD just love this stock
0 · Reply
biomaster22
biomaster22 Jun. 17 at 9:17 PM
$KOD a little perky today Mikey likes
0 · Reply
RandomInvestor777
RandomInvestor777 Jun. 17 at 8:10 PM
$KOD hoping this goes to 27 and below so i can load up in 60c for sept readout
0 · Reply
Stekli27
Stekli27 Jun. 17 at 4:41 PM
$KOD
1 · Reply
Bretm50
Bretm50 Jun. 17 at 3:39 PM
$KOD Super Bullish!!
0 · Reply
Cutlass
Cutlass Jun. 17 at 1:13 PM
$KOD Just hanging around - gap at 50 ✍️
1 · Reply
RandomInvestor777
RandomInvestor777 Jun. 14 at 12:42 AM
$KOD 80-110 range imo, but might drop to high 70's with big offering. Not sure about daybreak chances still. Think its more 60% Pos?
0 · Reply
RandomInvestor777
RandomInvestor777 Jun. 14 at 12:20 AM
$KOD going to 60-70 within next readout imo, and offering this time most likely This is a riskier readout than the one before (which was pretty much confirmed to be great due to prior trial)
0 · Reply
BB_88_
BB_88_ Jun. 12 at 9:07 PM
$KOD made sold my 29s grrr
1 · Reply